In the future, perhaps a simple blood test may be used to diagnose lung cancer and a breath test can determine the type. These findings were discussed as scientists shared knowledge at the Joint Conference on Molecular Origins of Lung Cancer in Coronado California on Wednesday.

These two lung cancer tests may be available in the future. The first is a blood test to determine if a patient has lung cancer.

Scientists have discovered a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

This breakthrough made by Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is critical since patients with small-cell lung cancer (SCLC) often do not get a second chance at therapies to combat this aggressive type of cancer.

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, will be presented today in San Diego at a joint conference of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).

This breakthrough is critical since patients with small-cell lung cancer (SCLC) often do not get a second chance at therapies to combat this aggressive type of cancer.

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, are being presented in San Diego at a joint conference of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).

Most of the people around the world die due to cancer, and one common cause that ties them together is lung cancer. The standard age for the diagnosis of this disease is sixty. Cancer can be broadly classified into two types, small cell (or coat cell) lung cancer and non-small cell lung cancer. The growth of small cell lung cancer is very quick and can easily spread to the other body parts. This kind of lung cancer is most common among the smokers. The non-small cell lung cancer is further divided into three types; squamous cell carcinoma (a very common type of lung cancer), adenocarcinoma, and large cell carcinoma.

Lung cancer is basically uncontrollable growth of cancerous cells in the lungs. Small lumps of these cells make tumors which are very dangerous and sometimes deadly. It is the most common form of cancer due to which majority of cancer death takes place in United States and India.

Poniard Pharmaceuticals’(PARD Quote) cancer drug picoplatin failed to significantly prolong survival in patients with advanced small cell lung cancer, according to results of a pivotal study disclosed Monday.

The negative results sent Poniard shares plunging 77% to $1.70 in Monday’s pre-market trading session.

Small cell lung cancer patients treated with picoplatin had an 11% reduction in the risk of death compared to patients treated with best supportive care, but this survival benefit was not robust enough to be statistically significant.

Small-cell lung cancer is a disease sorely in need of better therapies. Now a study in mice has found a promising drug that may enter clinical trials in humans within a year.

One in five people with lung cancer has small-cell lung cancer. The disease has a poor long-term survival rate because the tumors spread quickly.

Celgene Corp said on Wednesday that pooled results from company-sponsored studies of its Amrubicin drug in relapsed small cell lung cancer showed it might be less toxic to the heart than traditional drugs in the same class.

After the close Friday, ImmunoGen, Inc. announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC). In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease.